Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
6 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
6
Trials led
0
Active
1,108
Total enrollment
3
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
3
Phase 2
1
Phase 3
2
Trials by status
Completed
3
Unknown
3
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes MellitusBMI 18.5-35Ph 3Completed506
The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes MellitusBMI ≤35Ph 3Unknown456